Actively Recruiting
Adaptive, Individualized Dose Escalation of Fluorouracil-Based Chemotherapy for Gastrointestinal Cancer Pilot Study of the FOX Regimen
Led by Dartmouth-Hitchcock Medical Center · Updated on 2026-06-22
36
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the feasibility of an adaptive, individualized dose escalation of 5-FU chemotherapy combined with oxaliplatin for patients with metastatic or locally advanced gastrointestinal cancers who tolerate initial doses well. This single-arm pilot study aims to assess the ability to increase 5-FU doses in patients without serious side effects at lower doses, focusing on colorectal, esophagus, appendix, small bowel, ampullary cancers, and other similar gastrointestinal malignancies. Participants receive the FOX regimen chemotherapy, which includes oxaliplatin 85 mgm2 and leucovorin calcium 350 mg intravenously on Day 1, along with a continuous infusion of 5-FU over 46 hours starting at 2,400 mgm2. The 5-FU dose is adaptively increased toward a maximum of 3,200 mgm2 across treatment cycles 2 to 4 using a clinical algorithm. This regimen is given in repeated 14-day cycles. During the study, participants are closely monitored through imaging of the chest, abdomen, and pelvis, blood tests, and assessments of chemotherapy response and safety. Researchers measure the proportion of patients who receive dose-intensified 5-FU by Cycle 6 and also track response rates, progression-free survival, drug exposure levels, and plasma uracil concentrations. The study continues for up to 12 months from treatment start, with safety and treatment effects carefully evaluated throughout.
CONDITIONS
Brief Title
Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer
Research Team
R
Research Nurse
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here